Neurochemical and neuropharmacological investigations with four ergot derivatives: bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712.
Neurochemical and neuropharmacological investigations with four ergot derivatives reveal differential pharmacodynamic effects of these compounds. Bromocriptine and CM 29-712 showed actions typical of postsynaptic dopamine receptor stimulants, in particular in the extrapyramidal system. CM 29-712 proved to be more potent than bromocriptine, with an early onset of action. CF 25-397 and dihydroergotoxine, while not showing all actions typical of central dopamine agonists, appeared to exert some of their effects by means of a stimulation of central serotoninergic sites. In the rat sleep-wakefulness cycles and in reserpine-induced ponto-geniculooccipital waves in the cat, they mimicked the effects of 5-hydroxytryptophan. In the latter test, CF 25-397 proved to be particularly potent. In addition, bromocriptine, dihydroergotoxine and CM 29-712 showed neurochemical effects consistent with central alpha-adrenergic blockade or an enhanced impulse flow in central noradrenergic neurons.
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D001971:Bromocriptine / Q000494:pharmacology; D002395:Catecholamines / Q000378:metabolism; D055598:Chemical Phenomena; D002621:Chemistry; D004088:Dihydroergotoxine / Q000494:pharmacology*; D004569:Electroencephalography; D004873:Ergolines / Q000494:pharmacology*; D006801:Humans; D008124:Locomotion / Q000187:drug effects; D008297:Male; D051379:Mice; D009020:Morphine / Q000037:antagonists & inhibitors; D009069:Movement Disorders / Q000139:chemically induced; D011817:Rabbits; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D012110:Reserpine; D012890:Sleep / Q000187:drug effects; D013239:Stereotyped Behavior / Q000187:drug effects
D002395:Catecholamines; D004873:Ergolines; D011954:Receptors, Dopamine; D004088:Dihydroergotoxine; D001971:Bromocriptine; D009020:Morphine; D012110:Reserpine